Harrison, NY16 Active Studies

Spinal Muscular Atrophy Clinical Trials in Harrison, NY

Find 16 actively recruiting spinal muscular atrophy clinical trials in Harrison, NY. Connect with local research sites and explore new treatment options.

16
Active Trials
3
Sponsors
1,326
Enrolling

Recruiting Spinal Muscular Atrophy Studies in Harrison

About Spinal Muscular Atrophy Clinical Trials in Harrison

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 16 spinal muscular atrophy clinical trials recruiting participants in Harrison, NY. These studies are seeking a combined 1,326 participants. Research is being sponsored by Taiho Oncology, Inc., Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI). Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Harrison — FAQ

Are there spinal muscular atrophy clinical trials in Harrison?

Yes, there are 16 spinal muscular atrophy clinical trials currently recruiting in Harrison, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Harrison?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Harrison research site will contact you about next steps.

Are clinical trials in Harrison free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Harrison studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 16 active trials in Harrison are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated October 12, 2026 from ClinicalTrials.gov